logo
Plus   Neg
Share
Email

Pharma News Today (TRVN,FPRX,TTPH)

Trevena, Inc. (TRVN) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for OLINVO (oliceridine), a moderate to severe acute pain reliever injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018.

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that on December 27, 2017, the company initiated dosing in the Phase 1 portion of the FIGHT Phase 1/3 clinical trial of FPA144, an isoform-selective anti-FGF receptor 2b antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric or gastroesophageal cancer.

Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant infections, announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for intravenous eravacycline for the treatment of complicated intra-abdominal infections.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Shares of Deutsche Bank were losing around 2 percent in German trading after the banking giant reported lower profit and revenues in its first quarter with weakness in all segments, mainly Corporate & Investment Bank. Separately, the bank announced actions to reshape its Corporate & Investment Bank and additional cost-cutting measures, including job cuts. Hershey Co. (HSY) on Thursday reaffirmed its adjusted earnings guidance for the full-year 2018 in the range of $5.33 to $5.43 range, an increase of 14 to 16 percent from 2017. However, reported earnings are now expected to be in the range of $4.73 to $4.98 per share, an increase of $0.02 per share... Automaker General Motors Co. on Thursday reported a 60 percent fall in profit for the first quarter from last year, reflecting lower revenues and a charge related to the company's Korean operations restructuring. However, adjusted earnings per share for the quarter beat analysts' estimates and the company affirmed its financial outlook for fiscal 2018.
Follow RTT